Physician Practice Roundup—Baselga takes helm of AstraZeneca’s cancer R&D
January 08, 2019 / Joanne Finnegan
Baselga takes helm of AstraZeneca’s cancer R&D as pharma rings in the new year with big changes Major changes are afoot at AstraZeneca as it shakes up its research structure with new units, new names and big moves. First up, we have José Baselga, who will run a newly formed cancer-focused unit. If that name sounds familiar, it's because Baselga was the target of pieces from ProPublica and The New York Times a few months back, alleging he had been getting paid by pharma companies for work but had not been disclosing it properly. He had been physician-in-chief at Memorial Sloan Kettering, but was forced out in the fall over the allegations—something he later took full responsibility for, although this didn’t save his job.